Lin, Gang

Publications

Sort by

Co-Author Network

selected publications

Dual-pharmacophore artezomibs hijack the Plasmodium ubiquitin-proteasome system to kill malaria parasites while overcoming drug resistance. Cell chemical biology. 2023 Academic Article GET IT
Times cited: 1
High-Throughput/High Content Imaging Screen Identifies Novel Small Molecule Inhibitors and Immunoproteasomes as Therapeutic Targets for Chordoma. Pharmaceutics. 2023 Academic Article GET IT
Times cited: 2
Structure of the human UBR5 E3 ubiquitin ligase. Structure (London, England : 1993). 2023 Academic Article GET IT
Times cited: 1
Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome. Cell chemical biology. 2023 Academic Article GET IT
Times cited: 1
A Study on Origin Traceability of White Tea (White Peony) Based on Near-Infrared Spectroscopy and Machine Learning Algorithms. Foods (Basel, Switzerland). 2023 Academic Article GET IT
Structure-Activity Relationship Studies of Antimalarial Plasmodium Proteasome Inhibitors─Part II. Journal of medicinal chemistry. 2023 Academic Article GET IT
Discovery of Highly Selective Inhibitors of the Human Constitutive Proteasome β5c Chymotryptic Subunit. Journal of medicinal chemistry. 2023 Academic Article GET IT
Times cited: 1
Susceptibilities of Ugandan Plasmodium falciparum Isolates to Proteasome Inhibitors. Antimicrobial agents and chemotherapy. 2022 Academic Article GET IT
Times cited: 3
Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors. Journal of medicinal chemistry. 2022 Academic Article GET IT
Times cited: 2
Microbial proteasomes as drug targets. PLoS pathogens. 2021 Review GET IT
Times cited: 9
Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome. Journal of medicinal chemistry. 2021 Academic Article GET IT
Times cited: 6
Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice. Angewandte Chemie (International ed. in English). 2021 Academic Article GET IT
Times cited: 13
Noncytotoxic Inhibition of the Immunoproteasome Regulates Human Immune Cells In Vitro and Suppresses Cutaneous Inflammation in the Mouse. Journal of immunology (Baltimore, Md. : 1950). 2021 Academic Article GET IT
Times cited: 5
Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides. Journal of medicinal chemistry. 2020 Academic Article GET IT
Times cited: 9
Activity of Epigenetic Inhibitors against Plasmodium falciparum Asexual and Sexual Blood Stages. Antimicrobial agents and chemotherapy. 2020 Academic Article GET IT
Times cited: 13
Immunoproteasome inhibitor DPLG3 attenuates experimental colitis by restraining NF-κB activation. Biochemical pharmacology. 2020 Academic Article GET IT
Times cited: 8
Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome. Journal of medicinal chemistry. 2019 Academic Article GET IT
Times cited: 13
Improvement of Asparagine Ethylenediamines as Anti-malarial Plasmodium-Selective Proteasome Inhibitors. Journal of medicinal chemistry. 2019 Academic Article GET IT
Times cited: 25
Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance. Proceedings of the National Academy of Sciences of the United States of America. 2018 Academic Article GET IT
Times cited: 51
Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes. Nature communications. 2017 Academic Article GET IT
Times cited: 39
The immunoproteasome: An old player with a novel and emerging role in alloimmunity. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2017 Review GET IT
Times cited: 33
Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome. Biochemistry. 2016 Academic Article GET IT
Times cited: 14
Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. Proceedings of the National Academy of Sciences of the United States of America. 2016 Academic Article GET IT
Times cited: 48
Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome. ACS infectious diseases. 2016 Academic Article GET IT
Times cited: 17
Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors. ChemMedChem. 2016 Academic Article GET IT
Times cited: 26
Identification and characterization of a constitutively expressed Ctenopharyngodon idella ADAR1 splicing isoform (CiADAR1a). Developmental and comparative immunology. 2016 Academic Article GET IT
Times cited: 2
Stressed mycobacteria use the chaperone ClpB to sequester irreversibly oxidized proteins asymmetrically within and between cells. Cell host & microbe. 2015 Academic Article GET IT
Times cited: 70
Ctenopharyngodon idella IRF2 plays an antagonistic role to IRF1 in transcriptional regulation of IFN and ISG genes. Developmental and comparative immunology. 2014 Academic Article GET IT
Times cited: 37
Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome. ACS medicinal chemistry letters. 2014 Academic Article GET IT
Times cited: 42
N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets. Journal of the American Chemical Society. 2013 Academic Article GET IT
Times cited: 44
Crossover inhibition as an indicator of convergent evolution of enzyme mechanisms: a β-lactamase and a N-terminal nucleophile hydrolase. FEBS letters. 2012 Academic Article GET IT
Times cited: 8
Fellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasome. Archives of biochemistry and biophysics. 2010 Academic Article GET IT
Times cited: 50
Structural basis for the assembly and gate closure mechanisms of the Mycobacterium tuberculosis 20S proteasome. The EMBO journal. 2010 Academic Article GET IT
Times cited: 33
Structural insights on the Mycobacterium tuberculosis proteasomal ATPase Mpa. Structure (London, England : 1993). 2009 Academic Article GET IT
Times cited: 64
Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. Journal of medicinal chemistry. 2009 Academic Article GET IT
Times cited: 106
Inhibitors selective for mycobacterial versus human proteasomes. Nature. 2009 Academic Article GET IT
Times cited: 188
Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates. The Journal of biological chemistry. 2008 Academic Article GET IT
Times cited: 44
A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis. Tuberculosis (Edinburgh, Scotland). 2008 Review GET IT
Times cited: 52
Selective killing of nonreplicating mycobacteria. Cell host & microbe. 2008 Academic Article GET IT
Times cited: 151
Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity. Molecular microbiology. 2006 Academic Article GET IT
Times cited: 92
Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate. Molecular microbiology. 2006 Academic Article GET IT
Times cited: 111
Characterization of a Mycobacterium tuberculosis proteasomal ATPase homologue. Molecular microbiology. 2005 Academic Article GET IT
Times cited: 112

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Hijacking Plasmodium ubiquitin-proteasome system to defeat drug resistance awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2023 - 2028
IpiNovyx Collaboration awarded by IpiNovyx Bio, Inc. Principal Investigator 2022 - 2024
Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2019 - 2024
Compounds that force Plasmodium falciparum to produce its own inhibitors awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2020 - 2023

Targeting the Plasmodium proteasome for prophylaxis and treatment of drug-resistant malaria in US Military personnel awarded by United States Department of Defense Principal Investigator Subaward 2022 - 2024

more ...

less ...

Background

education and training

Ph.D., West China University of Medical Sciences (China) 1997
M.Sc., Lanzhou University (China) 1994
B.S., Southwest Normal University (China) 1991

Contact

full name

Gang Lin

primary email

gal2005@med.cornell.edu

VIVO Weill Cornell Medical College

Gang Lin Associate Professor of Research in Microbiology and Immunology

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email